News
EUIPO Rejects PHŌNX Mark After Pharma Opposition
The European Union Intellectual Property Office Opposition Division issued a decision on October 30, 2026, upholding an opposition filed by Bulgarian company Фьоникс Фарма ЕООД (PHOENIX Pharma) against European Union trademark application No. 19 213 731 for PHŌNX.
The opposition succeeded on the ground of likelihood of confusion with the earlier PHOENIX Pharma mark. The Division found the signs confusingly similar despite differences in spelling, pronunciation, and appearance, and refused the application for all contested goods. The applicant was ordered to pay the opposition costs, fixed at €620.
The ruling relied on the earlier Bulgarian trademark registration held by PHOENIX Pharma. No examination of additional earlier rights was required once the primary ground succeeded. The decision underscores the protection afforded to established pharmaceutical marks against later applications that create a risk of consumer confusion.
IP Consulting represented the opponent and secured the full rejection. The outcome illustrates how EUIPO evaluates visual, phonetic, and conceptual similarities in opposition proceedings involving marks in the same or related fields.